NCT03432091View on ClinicalTrials.gov

Melatonin Receptor Agonist and Peripheral Biological Markers

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

January 11, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

July 31, 2019

Conditions
Insomnia
Interventions
DRUG

melatonin

Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders

All Listed Sponsors
lead

National Science and Technology Council, Taiwan

OTHER_GOV

NCT03432091 - Melatonin Receptor Agonist and Peripheral Biological Markers | Biotech Hunter | Biotech Hunter